Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06742723 · ClinicalTrials.gov registry record · Phase 3

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

A Phase 3 study of Chronic Kidney Disease and Hypertension, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
5,000
Enrollment target
20
Study locations

NCT06742723 is a Phase 3 study of Chronic Kidney Disease and Hypertension that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 5,000 participants. The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06742723, a Phase 3 study of Chronic Kidney Disease and Hypertension, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
5,000 participants
Enrollment target
20
Study locations

Study Summary

International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

Conditions Studied

Chronic Kidney Disease and Hypertension

Interventions

  • DRUG Baxdrostat/dapagliflozin
  • DRUG Placebo/dapagliflozin

Study Locations (20)

California

  • Research Site - Beverly Hills
  • Research Site - Canoga Park
  • Research Site - Concord
  • Research Site - Fremont
  • Research Site - Fullerton
  • Research Site - Inglewood
  • Research Site - Los Alamitos
  • Research Site - Los Angeles
  • Research Site - San Diego
  • Research Site - San Francisco
  • Research Site - Stanford
  • Research Site - Tarzana

Arizona

  • Research Site - Surprise
  • Research Site - Tucson

Colorado

  • Research Site - Arvada
  • Research Site - Denver

Alabama

  • Research Site - Fairhope

Connecticut

  • Research Site - New Britain

District of Columbia

  • Research Site - Washington D.C.

Florida

  • Research Site - Boca Raton

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2025-03-03
Est. Completion 2029-12-18
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06742723

The ClinicalTrials.gov registry entry for NCT06742723 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Kidney Disease and Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Baxdrostat/dapagliflozin is the first listed.

NCT06742723 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Arizona, Colorado.

Frequently Asked Questions

What is clinical trial NCT06742723 about?

NCT06742723 is a clinical study titled "A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure". International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

What is the current status of trial NCT06742723?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,000 participants. The study started on 2025-03-03. Estimated completion is 2029-12-18.

What conditions does trial NCT06742723 study?

This clinical trial studies the following conditions: Chronic Kidney Disease and Hypertension.

What interventions are being tested in trial NCT06742723?

The interventions under investigation include: Baxdrostat/dapagliflozin (DRUG), Placebo/dapagliflozin (DRUG).

Who is sponsoring clinical trial NCT06742723?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06742723 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Kidney Disease and Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Kidney Disease and Hypertension

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.